| Gregory Ayuk, PHARMD | |
|
4360 Bells Ferry Rd Nw, Kennesaw, GA 30144-1354 | |
| (678) 445-5064 | |
| Not Available |
| Full Name | Gregory Ayuk |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 4360 Bells Ferry Rd Nw, Kennesaw, Georgia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093099731 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 015512 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Gregory Ayuk, PHARMD 402 Second Street, Henderson, KY 42420 Ph: (270) 830-6502 | Gregory Ayuk, PHARMD 4360 Bells Ferry Rd Nw, Kennesaw, GA 30144-1354 Ph: (678) 445-5064 |
News Archive
Amgen Inc. today announced the publication of results from the first open-label study to compare Nplate® (romiplostim) treatment to standard of care therapies (SOC) in non-splenectomized adult patients with chronic immune thrombocytopenia (ITP). The study results, which were published today in the New England Journal of Medicine (NEJM), show that both the incidence of treatment failure and need for splenectomy were reduced among the Nplate-treated patients.
The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany.
Women who have been diagnosed with breast cancer believe the risk of the disease occurring in their unaffected breast is as much as ten times higher than it actually is. As a result, they are choosing to have prophylactic mastectomies based on a false perception of increased risk, according to new research.
In a surprising result, Michigan State University researchers looking at the effects of diet on bowel disease found that mice on a calorie-restricted diet were more likely to die after being infected with an inflammation-causing bacterial pathogen in the colon.
Enobia Pharma today announced positive results for its Phase II juvenile clinical trial of ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy intended for the treatment of hypophosphatasia (HPP). Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.
› Verified 2 days ago
Dr. Chad Richard, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2782 N Cobb Pkwy, Kennesaw, GA 30152 Phone: 770-420-1092 | |
Tara Thompson, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6095 Pine Mountain Rd Nw Ste 108, Kennesaw, GA 30152 Phone: 770-421-1399 | |
Avery Miller Berkhan, PHARMD, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 740 Ernest W Barrett Pkwy Nw, Kennesaw, GA 30144 Phone: 770-499-1018 | |
Dr. Kurt Howe, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6095 Pine Mountain Rd Nw, Kennesaw, GA 30152 Phone: 770-421-1399 | |
Dr. Adam Todd Mills, PHARM. D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2105 Barrett Park Dr Nw Ste 101, Kennesaw, GA 30144 Phone: 678-797-9067 Fax: 678-797-9066 | |
Dr. Katie Bozeman Moore, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4290 Bells Ferry Rd Nw, Kennesaw, GA 30144 Phone: 770-516-0686 Fax: 770-516-6035 | |
Oluwatosin Adebimpe Falola, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4075 Cherokee St Nw, Kennesaw, GA 30144 Phone: 770-528-5651 |